Kapila Anand - Elanco Animal Independent Director
ELAN Stock | USD 12.93 0.02 0.15% |
Director
Ms. Kapila K. Anand is an Independent director of the Company. Ms. Anand has served as a member of the Board since September 2018. Ms. Anand has served as a Senior Advisor to KPMG LLP, an accounting firm, since 2016. Prior to that, Ms. Anand served in various leadership roles as a partner at KPMG LLP, including Industry Segment Leader Travel, Leisure and Hospitality from 2011 to 2017, Partner in Charge Public Policy Business Initiatives from 2009 to 2013, KPMG LLP Board member from 2005 to 2010, Advisory Leader Private Equity, Real Estate and Hospitality from 2002 to 2009 and Audit Partner Real Estate and Hospitality from 1989 to 2002. Ms. Anand currently serves on the boards of directors of Extended Stay America, Inc. and Omega Healthcare Investors, Inc. Ms. Anands experience described above, including her extensive financial, managerial and corporate governance experience, provides her with the qualifications and skills to serve as a director on Elancos board. since 2018.
Age | 67 |
Tenure | 6 years |
Address | 2500 Innovation Way, Greenfield, IN, United States, 46140 |
Phone | 877 352 6261 |
Web | https://www.elanco.com |
Elanco Animal Management Efficiency
The company has return on total asset (ROA) of 0.0139 % which means that it generated a profit of $0.0139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1822) %, meaning that it created substantial loss on money invested by shareholders. Elanco Animal's management efficiency ratios could be used to measure how well Elanco Animal manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Capital Employed is likely to grow to 0.03, though Return On Tangible Assets are likely to grow to (0.24). As of the 23rd of April 2024, Asset Turnover is likely to grow to 0.33, while Total Assets are likely to drop about 13.6 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Paul Mitchell | Alkermes Plc | 64 | |
Grainne Troute | Evotec SE ADR | N/A | |
Anthony Quirk | Evotec SE ADR | N/A | |
Douglas Braunstein | Eagle Pharmaceuticals | 57 | |
David Anstice | Alkermes Plc | 69 | |
Michael Graves | Eagle Pharmaceuticals | 61 | |
Wendy Dixon | Alkermes Plc | 62 | |
Hamish Stevens | Evotec SE ADR | N/A | |
Floyd Bloom | Alkermes Plc | 80 | |
Steven Ratoff | Eagle Pharmaceuticals | 81 | |
Robert Breyer | Alkermes Plc | 73 | |
Nancy Wysenski | Alkermes Plc | 60 | |
Nancy Snyderman | Alkermes Plc | 66 | |
Lynda Reid | Evotec SE ADR | N/A | |
Robert Glenning | Eagle Pharmaceuticals | 57 | |
Sander Flaum | Eagle Pharmaceuticals | 81 | |
Richard Edlin | Eagle Pharmaceuticals | 57 | |
David Pernock | Eagle Pharmaceuticals | 63 | |
Alain Schreiber | Eagle Pharmaceuticals | 58 | |
Edward Kay | Eagle Pharmaceuticals | N/A | |
Norah Barlow | Evotec SE ADR | N/A |
Management Performance
Return On Equity | -0.18 | ||||
Return On Asset | 0.0139 |
Elanco Animal Health Leadership Team
Elected by the shareholders, the Elanco Animal's board of directors comprises two types of representatives: Elanco Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elanco. The board's role is to monitor Elanco Animal's management team and ensure that shareholders' interests are well served. Elanco Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elanco Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jose Simas, Executive Vice President U.S. Farm Animal Business | ||
Joshua Smiley, Independent Director | ||
Chris Keeley, Senior Officer | ||
Carl McMillian, Independent Director | ||
Katy Grissom, Head Relations | ||
Ellen Brabander, Executive Vice President - Innovation and Regulatory Affairs | ||
Sarena Lin, Executive Vice President, Global Marketing, Corporate Strategy and Transformation | ||
Paul Herendeen, Independent Director | ||
Racquel Mason, Executive Vice President and Chief Marketing Officer, Elanco Animal Health | ||
Rajeev Modi, Executive Vice President - U.S. Pet Health and Global Digital Transformation | ||
Jeffrey Simmons, President, Chief Executive Officer, Director | ||
Denise ScotsKnight, Independent Director | ||
David Kinard, Executive Vice President, Human Resources, Corporate Affairs and Administration | ||
David Urbanek, Executive Vice President - Manufacturing, Quality | ||
Aaron Schacht, Executive Vice President, Innovation, Regulatory and Business Development | ||
R Hoover, Independent Chairman of the Board | ||
Larbi Lier, Senior Asia | ||
Kirk McDonald, Independent Director | ||
James Meer, Senior Vice President, Chief Accounting Officer | ||
Art Garcia, Independent Director | ||
Shiv ONeill, General President | ||
Joyce Lee, Executive Vice President and President U.S. Pet Health and Commercial Operations | ||
David Hoover, Chairman of the Board | ||
Kapila Anand, Independent Director | ||
Michael Harrington, Independent Director | ||
Todd Young, Chief Financial Officer, Executive Vice President | ||
David Ricks, Independent Director | ||
Marcela Kirberger, Executive Vice President General Counsel, Company Secretary | ||
Scott Ferguson, Independent Director | ||
Shawn McKee, Sr Animal | ||
Deborah Kochevar, Independent Director | ||
Lawrence Kurzius, Independent Director | ||
Ramiro Cabral, Executive Vice President - Elanco International and Global Customer Value | ||
Aarti Shah, Independent Director | ||
Dirk Ehle, Executive Vice President and President Elanco Europe | ||
William Doyle, Independent Director | ||
John Bilbrey, Independent Director | ||
MichaelBryant Hicks, Executive Vice President General Counsel, Secretary |
Elanco Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elanco Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.18 | ||||
Return On Asset | 0.0139 | ||||
Profit Margin | (0.28) % | ||||
Operating Margin | 0.02 % | ||||
Current Valuation | 11.95 B | ||||
Shares Outstanding | 492.97 M | ||||
Shares Owned By Insiders | 0.65 % | ||||
Shares Owned By Institutions | 99.13 % | ||||
Number Of Shares Shorted | 12.47 M | ||||
Price To Earning | 241.75 X |
Elanco Animal Investors Sentiment
The influence of Elanco Animal's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Elanco. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Elanco Animal's public news can be used to forecast risks associated with an investment in Elanco. The trend in average sentiment can be used to explain how an investor holding Elanco can time the market purely based on public headlines and social activities around Elanco Animal Health. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Elanco Animal's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Elanco Animal's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Elanco Animal's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Elanco Animal.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Elanco Animal in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Elanco Animal's short interest history, or implied volatility extrapolated from Elanco Animal options trading.
Pair Trading with Elanco Animal
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elanco Animal position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elanco Animal will appreciate offsetting losses from the drop in the long position's value.Moving together with Elanco Stock
0.63 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Elanco Stock
0.73 | ELYM | Eliem Therapeutics | PairCorr |
0.52 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Elanco Animal could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elanco Animal when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elanco Animal - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elanco Animal Health to buy it.
The correlation of Elanco Animal is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elanco Animal moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elanco Animal Health moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elanco Animal can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elanco Animal Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Elanco Animal Health information on this page should be used as a complementary analysis to other Elanco Animal's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Elanco Stock analysis
When running Elanco Animal's price analysis, check to measure Elanco Animal's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elanco Animal is operating at the current time. Most of Elanco Animal's value examination focuses on studying past and present price action to predict the probability of Elanco Animal's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elanco Animal's price. Additionally, you may evaluate how the addition of Elanco Animal to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
CEOs Directory Screen CEOs from public companies around the world |
Is Elanco Animal's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elanco Animal. If investors know Elanco will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elanco Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.097 | Earnings Share (2.50) | Revenue Per Share 8.972 | Quarterly Revenue Growth 0.051 | Return On Assets 0.0139 |
The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elanco Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elanco Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elanco Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.